Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving virus or bacteriophage
Reexamination Certificate
1995-05-11
2002-07-09
Wortman, Donna C. (Department: 1648)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving virus or bacteriophage
C435S006120, C436S820000
Reexamination Certificate
active
06416944
ABSTRACT:
FIELD OF THE INVENTION
This invention relates to typing hepatitis C viruses (HCV). In particular, this invention relates to a method of typing HCV using novel type specific polypeptides.
BACKGROUND OF THE INVENTION
Viral hepatitis is known to be caused by five different viruses known as hepatitis A, B, C, D and E. HAV is an RNA virus and does not lead to long-term clinical symptoms. HBV is a DNA virus. HDV is a dependent virus that is unable to infect cells in the absence of HBV. HEV is a water-borne virus. HCV was first identified and characterized as a cause of non-A, non-B hepatitis (NANBH). Houghton et al., EPO Pub. No. 388,232. This led to the disclosure of a number of general and specific polypeptides useful as immunological reagents in identifying HCV. See. e.g., Choo et al. (1989)
Science
, 244:359-362; Kuo et al. (1989)
Science
, 244:362-364; and Houghton et al. (1991)
Hepatology
, 14:381-388. HCV is the major cause of blood transfusion-related hepatitis.
The prototype isolate of HCV was characterized in EP Publication Nos. 318,216 and 388,232. As used herein, the term “HCV” includes newly isolated NANBH viral species. The term “HCV-1” refers to the virus described in the above-mentioned publications.
Since the initial identification of HCV, at least six different viral types have been identified and designated HCV-1 to HCV-6. Cha et al. (1992)
Proc. Natl. Acad. Sci. USA
, 89:7144-7148. Within these types are numerous subtypes. The type of virus with which a patient is infected may affect the clinical prognosis and also response to various treatments. Yoshioka et al. (1992)
Hepatology
, 16:293-299. In light of the fact that the most serious clinical outcome of HCV infection is hepatocellular carcinoma, it would be useful to be able to determine with which type or types of HCV a patient is infected.
The method currently in use to determine virus type is genotyping; that is, isolation of viral RNA and determination of the sequence of various segments by polymerase chain reaction (PCR). Not only is this method laborious and time consuming but it is not suitable for use on samples that have been stored under conditions that do not allow for preservation of RNA or samples from patients that do not have sufficient viral titer. It would be useful to have a method for typing HCV by immunoanalysis or serotyping.
The current method for screening blood and diagnosing patients is an immunoassay. The immunoassay utilizes an antigen from HCV-1 which contains a sufficient number of common epitopes to detect antibodies to other types of HCV. The immunoassay does not distinguish between infections by different types of HCV.
SUMMARY OF THE INVENTION
The present invention includes compositions and methods for typing of HCVs by genotype and serotype. The compositions include type specific epitopes, type-cluster specific epitopes, nucleic acids encoding the epitopes for use as probes and nucleic acids complementary to the regions flanking those encoding the epitopes for use as primers.
One aspect of the invention is a method for typing HCV comprising, the steps of providing an antibody-containing sample from an individual; contacting the sample with a type specific epitope or type-cluster specific epitopes under conditions which permit antigen-antibody binding; and determining whether antibodies in the sample bind to the epitope.
Another aspect of the invention relates to a method for typing HCV comprising the steps of providing an antibody-containing sample from an individual; contacting the sample with a first type specific epitope or type-cluster specific epitope under conditions which permit antigen-antibody binding; contacting the sample with a second type specific epitope or type-cluster specific epitope under conditions which permit antigen-antibody binding; and determining whether antibodies in the sample bind to either the first or second epitope.
Another aspect of the invention relates to polypeptides containing type specific epitopes or type-cluster specific epitopes. The polypeptides are derived from three different regions of the HCV genome. One set of polypeptides includes type specific epitope or type-cluster specific epitopes obtained from the HCV core region. This first set is found between amino acid residues sixty-seven and eighty-four of HCV-1 and homologous regions of other types of HCV. As used herein, the amino acid residue abbreviations are as follows: A, alanine; I, isoleucine; L, leucine; M, methionine; F, phenylalanine; P, proline; W,. tryptophan; V, valine; N, asparagine; C, cysteine; Q, glutamine; G, glycine; S. serine; T. threonine; Y, tyrosine; R, arginine; H, histidine; K, lysine; D, aspartic acid; and E, glutamic acid.
The particular amino acid residue sequences derived from the core region and subtypes from which they are derived are as follows:
1. PEGRTWAQ (SEQ ID NO:3), subtype 1a or 1b.
2. STGKSWGK (SEQ ID NO:4), subtype 2a or 2b.
3. SEGRSWAQ (SEQ ID NO:5), subtype 3a or 4.
Another set of polypeptides includes a type specific epitope obtained from the HCV non-structural region 4 (NS4). This second set is found between amino acid residues 1689-1718 of HCV-1 and homologous regions of other types of HCV.
The particular amino acid residue sequences and types or subtypes from which they are derived are as follows:
1. CSQHLPY (SEQ ID NO:5), subtype 1a.
2. CASHLPY (SEQ ID NO:7), subtype 1b.
3. CASRAAL (SEQ ID NO:8), subtype 2a or 2b.
4. CASKAAL (SEQ ID NO:23)
Another set of polypeptides includes type specific epitope or type-cluster specific epitopes obtained from the non-structural region 5 (NS5) of a hepatitis C virus. This set is found between amino acid residues 2281-2313 of HCV-1 and homologous regions of other types of hepatitis C virus.
The particular amino acid residue sequences and types or subtypes from which they are derived are as follows:
1. PDYEPPVVHG (SEQ ID NO:9), subtype 1a.
2. PDYVPPVVHG (SEQ ID NO:10), subtype 1b.
3. PDYQPATVAG (SEQ ID NO:11), subtype 2a.
4. PGYEPPTVLG (SEQ ID NO:12), subtype 2b.
5. FAQASPVW (SEQ ID NO:13), subtype 1a.
6. FPPQALPIW (SEQ ID NO:14), subtype 1b.
7. FPPQALPAW (SEQ ID NO:15), subtype 2a.
8. FPPQALPPW (SEQ ID NO:16), subtype 2b.
Another aspect of the invention includes nucleic acid molecules encoding the amino acid residue sequences of the type specific and type-cluster epitopes described. These nucleic acid molecules are useful as probes for instance in Southern blots or other DNA recognition assays such as the capture assay described in U.S. Pat. Nos. 4,868,105; and 5,124,246.
Another aspect of the invention includes nucleic acid molecules complementary to the nucleic acid sequences flanking regions encoding the type specific and type-cluster specific epitopes. Such nucleic acid molecules are useful: in performing PCR to determine the genotype of a particular HCV.
REFERENCES:
patent: 4868105 (1989-09-01), Urdea et al.
patent: 5106726 (1992-04-01), Wang
patent: 5124246 (1992-06-01), Urdea et al.
patent: 5350671 (1994-09-01), Houghton et al.
patent: 5427909 (1995-06-01), Okamoto
patent: 5527669 (1996-06-01), Resnick et al.
patent: 318216 (1989-05-01), None
patent: 388232 (1990-09-01), None
patent: 0 586 065 (1994-03-01), None
patent: 91/15771 (1991-10-01), None
patent: 93/00365 (1993-01-01), None
patent: 93/06247 (1993-04-01), None
patent: 93/10239 (1993-05-01), None
patent: 94/11388 (1994-05-01), None
patent: WO 94/25602 (1994-11-01), None
Mondelli et al., Hepatitis C Virus (HCV) Core Serotypes in Chronic HCV Infection. Journal of Clinical Microbiology 32(10):2523-2527, 1994.*
Chan et al., Analysis of a new hepatitis C virus type and its phylogenetic relationship to existing variants, J. Gen. Virol. 73:1131-1141, 1992.*
Okamoto et al., Full-length Sequence of a Hepatitis C Virus Genome Having Poor Homology to Reported Isolates: Comparative Study of Four Distinct Genotypes, Virology 188:331-341, 1992.*
Chan et al., Serological responses to infection with three different types of hepatitis C virus, Lancet 338:1391, 1991.*
Cruse et al.,Illustrated Dictionary of Immunology. CRC Press, Boca Raton, 1995, p. 25
Chien David Y.
Kuo George
Blackburn Robert P.
Chiron Corporation
Harbin Alisa A.
Robins Roberta L.
Wortman Donna C.
LandOfFree
Methods of typing hepatitis C virus and reagents for use... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of typing hepatitis C virus and reagents for use..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of typing hepatitis C virus and reagents for use... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2883082